Roivant Sciences ROIV 深 滬
等待開盤 11-04 09:30:00 美东时间
36.04
+0.150
+0.42%
華盛通- 最 高36.78
- 今 開35.89
- 成交量 668.66万股
- 最 低 35.56
- 昨 收 35.89
- 總市值 260.33亿
- 52周最高 42.50
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 19.96
- 委 比 12.00%
- 總股本 7.22亿
- 歷史最高 42.50
- 量 比 1.27
- 振 幅 3.40%
- 歷史最低 2.52
- 每 手 1
- 風險率 5.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy Gift
Roivant Social Ventures (RSV) has partnered with No Patient Left Behind (NPLB) to enhance drug affordability and access while supporting medical innovation through a significant donation. RSV, a nonprofit focused on improving healthcare access, is transitioning its mission to NPLB, which aims to reduce out-of-pocket costs, preserve drug development incentives, and ensure timely generic drug availability. Both organizations are committed to ensuri...
10-29 13:00
Why Is Roivant Sciences Stock Surging Wednesday?
Roivant Sciences Ltd. (NASDAQ:ROIV) and its subsidiary Priovant Therapeutics announced positive results Wednesday from two Phase 3 trials evaluating brepocitinib for noninfectious uveitis (NIU), an inflammatory eye disease that can cause permanent vision loss. The investigational therapy achieved it...
10-22 01:14
Roivant Sciences shares are trading higher after the company announced that Brepocitinib met the primary endpoint for both the CLARITY-1 and CLARITY-2 studies and achieved statistically significant and clinically meaningful benefit on all key secondary endpoints.
Roivant Sciences shares are trading higher after the company announced that Brepocitinib met the primary endpoint for both the CLARITY-1 and CLARITY-2 studies and achieved statistically significant and clinically meaningful benefit on all key secondary endpoints.
10-21 20:44
Roivant reports strong Phase 3 data in uveitis
Roivant Sciences ( ($ROIV) ) has issued an update. On October 21, 2026, Roivant...
10-21 19:29
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Immunovant, Inc. announced it will report its second fiscal quarter financial results for the period ended September 30, 2026 on November 9, 2026 before market open. Roivant Sciences Ltd., Immunovant's majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that day, including a business update for Immunovant. Registration details and webcast information are available on the Immunovant website. Immunovant is a clinical-...
10-21 11:00
Roivant Sciences added to Citi's 90-day catalyst watch
Citi has added Roivant Sciences (ROIV) to its 90-day positive catalyst watch due to a release of topline data from the phase 3 CLARITY trial for brepocitinib in non-infectious uveitis coming later thi...
10-13 22:56
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BTIG analyst Douglas Harter downgraded UWM Holdings Corp (NYSE:UWMC) from Buy to Neutral. UWM Hol...
10-12 21:03
Wolfe Research Downgrades Roivant Sciences to Peer Perform
Wolfe Research analyst Andy Chen downgrades Roivant Sciences (NASDAQ:ROIV) from Outperform to Peer Perform.
10-12 20:10
Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 27.07% on an annualized basis producing an average annual return of 39.09%. Currently, Roivant Sciences has a market capitalization of $25.77 billion. Buying $1000 In ROIV: If an investor had bought $1000 of ROIV sto...
10-02 07:15
Immunovant Ends Autoimmune Skin Disorder Program
Roivant Sciences Ltd. (NASDAQ:ROIV) announced that Immunovant Inc. (NASDAQ:IMVT) plans to halt the development of IMVT-1402 as a treatment for cutaneous lupus erythematosus (CLE). The decision follows recent proof-of-concept trial results that failed to reach statistical significance. Shares of both...
09-23 21:03
